
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
VALEO PHARMA INC.CL.A VP2 CA91915B1085 BAW/UFN
© 2024 Xetra Newsboard
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
07.02. | Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc. | ||
20.11.24 | XFRA DELETION OF INSTRUMENTS FROM XETRA - 20.11.2024 | The following instruments on XETRA do have their last trading day on 20.11.2024Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 20.11.2024ISIN NameFR0013244415 BPIFRANCE 17/24 MTNFR0012159812... ► Artikel lesen | |
02.10.24 | XFRA VP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILVALEO PHARMA INC.CL.A... ► Artikel lesen | |
12.09.24 | Valeo Pharma Inc.: Valeo Pharma Reports Third Quarter 2024 Revenues | Q3-24 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23
Q3-24 adjusted EBITDA loss of $1.5 million compared... ► Artikel lesen | |
13.06.24 | Valeo Pharma Inc.: Valeo Pharma Reports Record Second Quarter 2024 Revenues | Record Q2-24 revenues of $14.1 million, up 4% over Q2-23 outpacing revenue softness in several non-core brands
Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million for Q2-23, up 48%... ► Artikel lesen |